Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ
122.20
+1.78(+1.48%)
  • Volume:
    61,605
  • Bid/Ask:
    121.80/122.32
  • Day's Range:
    120.51 - 122.20

LGND Overview

Prev. Close
120.42
Day's Range
120.51-122.2
Revenue
208.41M
Open
120.4
52 wk Range
78.26-219.73
EPS
2.31
Volume
61,605
Market Cap
2.02B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
150,856
P/E Ratio
52.03
Beta
1.15
1-Year Change
-3.03%
Shares Outstanding
16,652,080
Next Earnings Date
Jul 29, 2021
What is your sentiment on Ligand Pharmaceuticals Incorporated?
or
Vote to see community's results!

Ligand Pharmaceuticals Incorporated News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuySellSell
SummaryStrong BuyStrong BuyBuySellNeutral

Ligand Pharmaceuticals Incorporated Company Profile

Ligand Pharmaceuticals Incorporated Company Profile

Employees
155

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company’s commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company’s partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Read More
  • Earnings today.
    0
    • this could be another short squeeze
      3
      • Just bought
        0
        • let wall street bets know about this
          3
          • easy 300, high growth profitable company with lots of shorties to squeeze
            0
            • short squeeze, after the good earning result?
              0
              • short squeeze?
                0
                • Buy now
                  0
                  • What in the world
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.